Sign in

CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company

Dianthus Therapeutics, Inc. /DE/

Sign in to watch
Ticker
DNTH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
929-999-4055
Business address
7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
Former names
Magenta Therapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$4,814,890
in 3 filings, $4.8M under 10b5-1 plans

Net −$4,814,890. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Randhawa Simrat −$2.5M EVP, Head of R&D sold 85% of stake
  2. CARR EDWARD −$2.0M CHIEF ACCOUNTING OFFICER sold 100% of stake
  3. Read Simon −$327K Director sold 100% of stake

Reading 44 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-09-17 CARR EDWARD CHIEF ACCOUNTING OFFICER Option exercise 10b5-1 +20,000 $17.88 $358K 20,000
2026-09-17 CARR EDWARD CHIEF ACCOUNTING OFFICER Sale 10b5-1 −7,928 $100.43 $796K 12,072
2026-09-17 CARR EDWARD CHIEF ACCOUNTING OFFICER Sale 10b5-1 −6,771 $101.37 $686K 5,301
2026-09-17 CARR EDWARD CHIEF ACCOUNTING OFFICER Sale 10b5-1 −3,501 $102.39 $358K 1,800
2026-09-17 CARR EDWARD CHIEF ACCOUNTING OFFICER Sale 10b5-1 −1,100 $103.20 $114K 700
2026-09-17 CARR EDWARD CHIEF ACCOUNTING OFFICER Sale 10b5-1 −700 $104.39 $73K 0
2026-09-17 CARR EDWARD CHIEF ACCOUNTING OFFICER Option exercise · Stock Option (Right to Buy) 10b5-1 −20,000 43,818
2026-09-01 Randhawa Simrat EVP, Head of R&D Option exercise 10b5-1 +7,500 $17.88 $134K 11,500
2026-09-01 Randhawa Simrat EVP, Head of R&D Option exercise 10b5-1 +6,249 $21.77 $136K 17,749
2026-09-01 Randhawa Simrat EVP, Head of R&D Option exercise 10b5-1 +9,375 $22.07 $207K 27,124
2026-09-01 Randhawa Simrat EVP, Head of R&D Sale 10b5-1 −2,600 $105.19 $273K 24,524
2026-09-01 Randhawa Simrat EVP, Head of R&D Sale 10b5-1 −7,215 $106.25 $767K 17,309
2026-09-01 Randhawa Simrat EVP, Head of R&D Sale 10b5-1 −13,309 $106.74 $1.4M 4,000
2026-09-01 Randhawa Simrat EVP, Head of R&D Option exercise · Stock Option (Right to Buy) 10b5-1 −7,500 56,776
2026-09-01 Randhawa Simrat EVP, Head of R&D Option exercise · Stock Option (Right to Buy) 10b5-1 −6,249 41,676
2026-09-01 Randhawa Simrat EVP, Head of R&D Option exercise · Stock Option (Right to Buy) 10b5-1 −9,375 87,500
2026-08-19 Read Simon Director Option exercise 10b5-1 +2,778 $18.36 $51K 2,778
2026-08-19 Read Simon Director Sale 10b5-1 −2,778 $117.55 $327K 0
2026-08-19 Read Simon Director Option exercise · Stock Option (Right to Buy) 10b5-1 −2,778 19,445
2026-08-13 Veness Adam M SVP, General Counsel and Sec. Option exercise +15,000 $18.17 $273K 15,000

Page 1 of 18 · 355 trades